1-3 of 3
Kelsey Alvarez, RN
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study

Raajit K. Rampal, MD PhD, Srdan Verstovsek, MD PhD, Sean M. Devlin, PhD, Amber C. King, PharmD, BCOP, Eytan M. Stein, MD, Naveen Pemmaraju, MD, Michael J. Mauro, MD, Tapan M. Kadia, MD, Guillermo Montalban-Bravo, MD, Kelsey Alvarez, RN, Nicole Ard, Tawni Goodman, Bria Taylor, Prithviraj Bose, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4163.
https://doi.org/10.1182/blood-2019-127661
Published: 2019
Journal Articles

Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: Initial Results of a Phase II Study

Raajit K. Rampal, MD PhD, Srdan Verstovsek, MD PhD, Sean M Devlin, PhD, Eytan M. Stein, MD, Tapan M. Kadia, MD, Michael J. Mauro, MD, Naveen Pemmaraju, MD, Kelsey Alvarez, RN, Nicole Ard, Tawni Goodman, Kelly Marek, Prithviraj Bose, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 354.
https://doi.org/10.1182/blood-2018-99-114125
Published: 2018
Journal Articles

Selinexor, a First-in-Class XPO1 Inhibitor, Is Efficacious and Tolerable in Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents

Justin Taylor, MD, Morgan Coleman, MPH, Kelsey Alvarez, RN, Janine Pichardo, Filiz Sen, MD, Stephen S. Chung, MD, Raajit K. Rampal, MD PhD, Jae H. Park, MD, Eytan M. Stein, MD, Martin S. Tallman, MD, Omar I Abdel-Wahab, MD, Virginia M. Klimek, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 233.
https://doi.org/10.1182/blood-2018-99-113840
Published: 2018